Skip to main content
SpringerLink
Log in

Eptinezumab: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Eptinezumab-jjmr (referred to as eptinezumab hereafter; Vyepti™) is a humanised monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the receptor. CGRP is believed to play a major role in the pathophysiology of migraine. Eptinezumab, delivered by intravenous (IV) administration, is being developed by Lundbeck Seattle BioPharmaceuticals for the prevention of migraine. In February 2020, eptinezumab was approved in the USA for the preventive treatment of migraine in adults. This article summarizes the milestones in the development of eptinezumab leading to this first approval.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003;4(5):386–98.

    Article  CAS  Google Scholar 

  2. Durham PL, Vause CV. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs. 2010;24(7):539–48.

    Article  CAS  Google Scholar 

  3. Lundbeck. Vyepti (eptinezumab-jjmr): US prescribing Information. 2020. https://www.lundbeck.com/upload/us/files/pdf/Products/Vyepti_PI_US_EN.pdf. Accessed 5 Mar 2020.

  4. Lundbeck. FDA approves Lundbecks VYEPTI™ (eptinezumab-jjmr): the first and only intravenous preventive treatment for migraine [media release]. 2020. https://www.lundbeck.com.

  5. Alder B. Alder BioPharmaceuticals® enters into European patent settlement and global license agreement with Teva in the field of anti-CGRP-based therapy [media release]. https://investor.alderbio.com/news-releases/news-release-details/alder-biopharmaceuticalsr-enters-european-patent-settlement-and. Accessed 8 Jan 2018.

  6. Lundbeck AS. Lundbeck completes the acquisition of Alder BioPharmaceuticals—a company committed to transforming migraine treatment and prevention [media release]. https://www.lundbeck.com. Accessed 22 Oct 2019.

  7. Data on file, Lundbeck Seattle Biopharmaceuticals, Inc. 2020.

  8. Latham J, Karasek C, Ojala E, et al. Characterization of the intrinsic binding features of three anti-CGRP therapeutic antibodies effective in preventing migraine: a comparative case study of ALD403, Ly-2951742, TEV-48125 [abstract no. PS74LB]. Headache. 2016;56(8):1398.

    Google Scholar 

  9. Baker B, Schaeffler B, Beliveau M, et al. Population pharmacokinetics of eptinezumab for the preventive treatment of migraine [abstract no. IHC-DP-032]. Cephalalgia. 2019;39(1 Suppl):37.

    Google Scholar 

  10. Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020. https://doi.org/10.1177/0333102420905132.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Lipton RB, Saper J, Ashina M, et al. A phase 3 study to evaluate eptinezumab for the preventive treatment of chronic migraine: results of the PROMISE-2 (PRevention Of Migraine via Intravenous Eptinezumab Safety and Efficacy-2) trial [abstract no. PF02]. Headache. 2018;58(Suppl 2):80.

    Google Scholar 

  12. Kudrow D, Lipton R, Silberstein S, et al. Eptinezumab for prevention of chronic migraine: results of 2 infusions in the phase 3 PROMISE-2 (prevention of migraine via intravenous eptinezumab safety and efficacy-2) trial [abstract no. P2.10-006]. Neurology. 2019;92(15 Supplement):5.

    Google Scholar 

  13. Schim J, Goadsby P, Kassel E, et al. Eptinezumab increases days free from canonical migraine-associated symptoms within 1 month of treatment in patients with chronic Migraine [abstract no. P4.10-024]. Neurology. 2019;92(15 Suppl):20.

    Google Scholar 

  14. Cady R, McGill L, Hirman J, et al. Patient global impression of change related to improvement in most bothersome symptom following treatment with eptinezumab [abstract no. S38.009]. Neurology. 2019;92(15 Suppl):20.

    Google Scholar 

  15. Nagy AJ, Silberstein SD, Cady R, et al. Treatment with eptinezumab demonstrated meaningful improvements in patients with chronic migraine experiencing a high frequency of severe migraines [abstract no. P219LB]. Headache. 2019;59(Suppl 1):163.

    Google Scholar 

  16. Lipton RB, McGinley JS, Houts C, et al. Eptinezumab demonstrated early and sustained reductions in HIT-6 total score over time in patients with chronic migraine in the PROMISE-2 trial [abstract no. P215LB]. Headache. 2019;59(Suppl 1):159–60.

    Google Scholar 

  17. McGinley JS, Buse D, Wirth R, et al. Early and sustained reduction in headache impact in people with CM after eptinezumab treatment: HIT-6 item analysis in the phase 3 PROMISE-2 trial [abstract no. P216LB]. Headache. 2019;59(Suppl 1):160–1.

    Google Scholar 

  18. Lipton RB, McGinley JS, Hirman J, et al. HIT-6 responder rates after 1 and 3 months of eptinezumab treatment [abstract no. IHC-OR-018]. Cephalalgia. 2019;39(1 Suppl):12–3.

    Google Scholar 

  19. Winner P, McAllister P, Kassel E, et al. Eptinezumab reduces migraine frequency within the first month after treatment in patients with episodic or chronic migraine [abstract no. P1.10-023]. Neurology. 2019;92(15 Suppl):20.

    Google Scholar 

  20. Kudrow D, Diamond M, McGill L, et al. Eptinezumab achieved meaningful reductions in migraine activity as early as day 1:PROMISE-2 (prevention of migraine via intravenous eptinezumab safety and efficacy-2) phase 3 trial in chronic migraine [abstract no. IOR04]. Headache. 2018;58(Suppl 2):74

    Google Scholar 

  21. Winner PK, McAllister P, Cady R, et al. Migraine-free months in patients with episodic or chronic migraine treated with eptinezumab: results from the PROMISE-1 and PROMISE-2 trials [abstract no. P217LB]. Headache. 2019;59(Suppl 1):162.

    Google Scholar 

  22. Tepper SJ, Smith T, Kassel E, et al. Eptinezumab reduces the frequency of acute medication usage in patients with episodic or chronic migraine [abstract no. P218LB]. Headache. 2019;59(Suppl 1):162–3.

    Google Scholar 

  23. Chakhava G, Cady R, Kassel E, et al. Consistent reductions in migraine frequency with eptinezumab treatment in patients with migraine stratified by disease characteristics: subgroup analysis of PROMISE-1 and PROMISE-2 [abstract no. A42]. J Headache Pain. 2019;20(Suppl 1):20.

    Google Scholar 

  24. Janelidze M, Giorgadze G, Cady R, et al. Consistent reductions in migraine frequency with eptinezumab treatment in patients with migraine stratified by intrinsic factors: subgroup analyses of PROMISE-1 and PROMISE-2 [abstract no. A45]. J Headache Pain. 2019;20(Suppl 1):20.

    Google Scholar 

  25. Diamond M, Lipton R, Horblyuk R, et al. Early impact of Eptinezumab on the health-related quality of life (HRQoL) of patients with episodic or chronic Migraine: SF-36 analysis across the spectrum of migraine [abstract no. P1.10-025]. Neurology. 2019;92(15 Suppl):20.

    Google Scholar 

  26. Diamond M, Lipton RB, Horblyuk R, et al. Impact of eptinezumab on the health-related quality of life (HRQoL) of patients with episodic or chronic migraine: SF-36 analysis by months 1 and 3 across the spectrum of migraine [abstract no. PND82]. Value Health. 2019;22(Suppl 2):S285.

    Article  Google Scholar 

  27. Tepper S, Kudrow D, Horblyuk R, et al. Early migraine response by month 1 and clinically meaningful improvements in health-related quality of life (HRQOL) in patients with migraine in phase 3 trials of eptinezumab [abstract no. P2.10-020]. Neurology. 2019;92(15 Suppl 1):20.

    Google Scholar 

  28. Spierings E, Biondi D, Hirman J, et al. Reduced impact of headaches after migraine preventive treatment with eptinezumab in patients with chronic migraine: results from the PREVAIL open-label safety study [abstract no. P16]. Headache. 2019;59(Suppl 1):36.

    Google Scholar 

  29. Kudrow D, Berman G, Kassel E, et al. Eptinezumab treatment for migraine prevention reduces migraine disability in patients with chronic migraine: an analysis from the PREVAIL open-label safety study [abstract no. P17]. Headache. 2019;59(Suppl 1):36–7.

    Google Scholar 

  30. Kassel E, Huffman C, Hirman J, et al. Eptinezumab improved health-related quality of life in patients with chronic migraine in the open-label PREVAIL study [abstract no. P138]. Headache. 2019;59(Suppl 1):112.

    Google Scholar 

  31. Allan B, Khan A, Song Y, et al. PREVAIL: an open-label phase 3 trial to evaluate the safety of eptinezumab administered intravenously in patients with chronic migraine [abstract no. P125]. Headache. 2019;59(Suppl 1):105.

    Google Scholar 

  32. Song Y, Biondi D, Cady R, et al. An open-label phase 3 trial to evaluate the safety of eptinezumab administered intravenously in patients with chronic migraine (PREVAIL): demographics and baseline characteristics [abstract no. P158]. Headache. 2019;59(Suppl 1):121–2.

    Google Scholar 

  33. Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic Migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13(11):1100–7.

    Article  CAS  Google Scholar 

  34. Dodick DW, Lipton RB, Silberstein S, et al. Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia. 2019;39(9):1075–85.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

    Sohita Dhillon

Authors
  1. Sohita Dhillon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sohita Dhillon.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. S. Dhillon is a contracted employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

Enhanced material for this AdisInsight Report can be found at https://doi.org/10.6084/m9.figshare.12037707.

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhillon, S. Eptinezumab: First Approval. Drugs 80, 733–739 (2020). https://doi.org/10.1007/s40265-020-01300-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-020-01300-4

Search

Navigation